Chinese cancer drug developer BeiGene will create production cell lines using a platform developed by Sigma Aldrich's custom manufacturing services business.
China-based CDMO WuXi PharmaTech unveiled Thursday that it will soon begin construction on its third cell therapy manufacturing facility -- a 145,000-square-foot cGMP facility in Philadelphia.
Ancient nomadic kings’ love of life in the saddle did not hamper another of their favourite pastimes according to a study suggesting millions of Asian men are descended from just 11 fathers.
US desire for an alternative to the current multi-shot anthrax vaccine is a boon for delivery systems firm Glide Technologies, which had its contract extended by Pfenex this week.
CureVac will build a manufacturing facility for mRNA vaccines after a $52m (€46m) Gates Foundation investment that also brings an IPO one step closer according to majority shareholder Dietmar Hopp.
The UK has granted £20m ($31m) to the biotech industry – including Horizon, FujiFilm, and Cobra Biologics, to bring mAb, cell expression, and antibiotic projects to market.
Shire has acquired privately-held Meritage for an upfront fee of $70m and additional contingent payments based on the achievement of development and regulatory milestones.
Seattle-based Infectious Disease Research Institute (IDRI) has received $4m in funding from the US Biomedical Advanced Research and Development Authority (BARDA) to develop an adjuvant manufacturing hub with both preclinical and clinical expertise to...
Novasep has signed a €4.7m ($5.4m) agreement with Celladon, a clinical-stage biotechnology company, to prepare to supply the drug substance for the heart failure treatment Mydicar.
Having shorter hair stops you becoming fat…at least it does if you are a stem cell say researchers who claim restricting the growth of hair-like cilia found on such cells could yield new treatments for obesity.
Fresh of its acquisition of Novartis’ vaccine business, GlaxoSmithKline is doubling down with the purchase of GlycoVaxyn AG, a Swiss-based specialist vaccine maker, for $190m (£124m).
Boehringer-Ingelheim has renewed its collaboration with VTU technology to develop a yeast-based protein expression system for biopharmaceutical production.
update: WHO says tech like Nanopatch can help get vaccines to the people that need them
The Scripps Research Institute has created a nicotine conjugate vaccine with a technique it says could also treat cocaine, heroin, and methamphetamine addiction.
Contract manufacturer Piramal recently approved a $20m capacity expansion for hormonal and antibody drug conjugate (ADC) manufacturing at its facilities in Morpeth, UK, and Grangemouth, Scotland.
Cell therapy manufacturer NeoStem and contract manufacturer Invetech have agreed to develop a new closed processing system for cell therapy manufacturing.
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
The hype around developing new CAR-T (Chimeric Antigen Receptor transduced T) cell therapies, which can fight cancers by modifying patients’ immune cells, seemed to hit a new high this week, with two partnerships and an acquisition.
The $20m funding led by Pfizer Venture Investments will help advance a platform to make Probodies which CytomX says offers more precise tumour targeting than antibodies.
Sotio has selected local CRO Accord Research to carry out Phase I/II trials on its dendritic cell vaccines to treat patients with lung cancer in the Czech Republic.
Cancer and infectious disease immunotherapy developer Argos Therapeutics is collaborating with Saint-Gobain’s Performance Plastics division, to design, integrate and scale production of a range of disposables for use in the manufacturing of Argos’ lead...
Flu vaccine maker Protein Sciences, and Japan-based UMN Pharma and IHI Corp. have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan.
Korean and Harvard University scientists have developed a way to non–surgically inject programmable biomaterial to deliver a 3D vaccine that can more effectively treat diseases like cancer or HIV.
In a reversal from three years ago, the Court of Justice of the European Union (CJEU) ruled on Thursday that an organism incapable of developing into a human being is not a human embryo and may be patented.
Bruker Corp will pay $2.4m to settle US SEC charges that employees improperly funded Chinese officials' sightseeing trips to win analytical tech contracts at state labs.
Biopharma heavyweights Amgen, Pfizer and a number of other companies offered their unique takes on the biosimilar draft guidance from the EMA, calling for more clarity and some new additions before the final draft takes effect.
Richard the III was blond, blue-eyed and may owe a substantial parking fine based on new genetic research that solves a 529-year old missing persons case.
There is an upsurge in biopharma demand for cell and gene therapy applications, says Transposagen as it inks a deal with Janssen to develop allogeneic Chimeric Antigen Receptor (CAR) T-cells.
Merck has agreed to research, develop, manufacture, and distribute NewLink’s investigational Ebola vaccine candidate, which is currently in Phase I trials.
Amgen has completed construction of its first $200m next-gen biomanufacturing facility in Singapore, which is outfitted with single-use technology to allow for greater flexibility.
With the goal of developing a thermostable tuberculosis vaccine, IDRI (Infectious Disease Research Institute) was awarded a contract from the NIH’s National Institute of Allergy and Infectious Diseases that could be worth up to $11.9m.
UK researchers working with GSK say a newly identified immune cell communication mechanism could explain why some drugs don’t work and drive development of smaller, large molecule meds.
Collaboration does not mean drugmakers have started playing nice, it’s just that the pain of shared problems has become unbearable according to TransCelerate Biopharma CEO, Dalvir Gill.
Drug companies are looking for ways to put biologics in topical creams or “zap” them into skin using electricity as more large molecules come off patent.
There is no evidence that Ebola arrived on Earth from the stars, say a number of virologists, debunking media speculation that viruses had their origins in the Milky Way.
Isis Pharmaceuticals and AstraZeneca have expanded their partnership to develop novel delivery methods for antisense oligonucleotides in order to target the desired tissue more effectively.
